Includes all of these presentations from this session:

#	Presentation	Speaker
1	Is carginogenesis in Barrett’s esophagus a clonal evolution?	K.M. Das (New Brunswick)
2	Molecular Markers: “predictive” vs. “prognostic” vs. “signaling”. What is the difference?	J. Gibson (New Haven)
3	Research funding should be considered only if the biomarkers demonstrate a high potential for clinical relevance: Yes or No!	I. Parker (Cape Town)
4	Research funding should be considered even if the biomarkers have yet to demonstrate potential for clinical relevance. Yes or No!	T.E Godfrey (Boston)
5	The absolutely perfect biomarker for early detection of esophageal cancer: How would it affect morbidity & mortality?	H. Mashimo (Boston)
6	The absolutely perfect biomarker for treatment of esophageal cancer: How would it affect morbidity and mortality?	W. El-Rifai (Nashville)
7	Targeting Esophageal Cancer: A Genome Based Strategy	L. Mishra (Houston)
8	Will we ever succeed? Putting it all together	S.J. Sontag (Chicago)